US Pharma MarketingFDA hearing on Amgen's Tavneos will include findings from an independent review
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remain An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remains on the market. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning…
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remains on the market.
Source: FiercePharma